Smadar Kahana-Edwin
Overview
Explore the profile of Smadar Kahana-Edwin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
101
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kahana-Edwin S, Torpy J, Cain L, Mullins A, McCowage G, Woodfield S, et al.
Cancers (Basel)
. 2024 Jan;
16(1).
PMID: 38201440
Hepatoblastoma is characterized by driver mutations in , making it an attractive biomarker for a liquid biopsy approach utilizing circulating tumor DNA (ctDNA). This prospective observational study sought to ascertain...
2.
Grebstad Tune B, Sareen H, Powter B, Kahana-Edwin S, Cooper A, Koh E, et al.
Biomedicines
. 2023 Nov;
11(11).
PMID: 38001908
Genetic histone variants have been implicated in cancer development and progression. Mutations affecting the histone 3 (H3) family, H3.1 (encoded by and ) and H3.3 (encoded by ), are mainly...
3.
Perry G, Dadiani M, Kahana-Edwin S, Pavlovski A, Markus B, Hornung G, et al.
Mol Carcinog
. 2022 Sep;
61(11):1056-1070.
PMID: 36111610
Abnormal molecular processes occurring throughout the genome leave distinct somatic mutational patterns termed mutational signatures. Exploring the associations between mutational signatures and clinicopathological features can unravel potential mechanisms driving tumorigenic...
4.
Kahana-Edwin S, Cain L, McCowage G, Darmanian A, Wright D, Mullins A, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34282791
Background: amplification (MNA), segmental chromosomal aberrations (SCA) and activating mutations are biomarkers for risk-group stratification and for targeted therapeutics for neuroblastoma, both of which are currently assessed on tissue biopsy....
5.
Kahana-Edwin S, Cain L, Karpelowsky J
Biopreserv Biobank
. 2021 Jan;
19(2):124-129.
PMID: 33493007
Liquid biopsy is rapidly gaining traction for potentially revolutionizing cancer diagnosis and treatment through blood-based utilization of shed biomolecules. This approach can provide a global picture of the cancer in...
6.
Kahana-Edwin S, McCowage G, Cain L, Saletta F, Yuksel A, Graf N, et al.
Pediatr Blood Cancer
. 2020 Sep;
67(11):e28594.
PMID: 32881242
Driver mutations in the CTNNB1 gene (encoding β-catenin) are a hallmark of sporadic hepatoblastoma (HBL). Our results show that CTNNB1 circulating tumour DNA (ctDNA) is readily detected in patients diagnosed...
7.
Dadiani M, Necula D, Kahana-Edwin S, Oren N, Baram T, Marin I, et al.
Cancer Immunol Immunother
. 2020 Mar;
69(7):1315-1326.
PMID: 32198536
In view of the relatively limited efficacy of immunotherapies targeting the PD-1-PD-L1 axis in triple-negative breast cancer (TNBC) and of published reports on tumor-promoting roles of TNFR2+ tumor-infiltrating lymphocytes (TNFR2+...
8.
Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, et al.
Breast Cancer Res
. 2020 Mar;
22(1):28.
PMID: 32164744
After the publication of the original article [1], we were notified the upper panel of the Fig. 1, where the patients' codes are listed, was cropped by mistake so the...
9.
Zundelevich A, Dadiani M, Kahana-Edwin S, Itay A, Sella T, Gadot M, et al.
Breast Cancer Res
. 2020 Feb;
22(1):16.
PMID: 32014063
Background: Emerging mutations in the ESR1 gene that encodes for the estrogen receptor (ER) are associated with resistance to endocrine therapy. ESR1 mutations rarely exist in primary tumors (~ 1%)...
10.
Dadiani M, Bossel Ben-Moshe N, Paluch-Shimon S, Perry G, Balint N, Marin I, et al.
Clin Cancer Res
. 2016 Mar;
22(14):3651-62.
PMID: 26957561
Purpose: Molecular evolution of tumors during progression, therapy, and metastasis is a major clinical challenge and the main reason for resistance to therapy. We hypothesized that microRNAs (miRNAs) that exhibit...